| | Evaluation of NucliSens EasyQ™ HIV-1 assay for quantification of HIV-1 subtypes prevalent in South-east AsiaReceived 24 June 2006; received in revised form 6 October 2006; accepted 6 October 2006. published online 17 November 2006. Abstract BackgroundMonitoring anti-retroviral therapy requires that viral load assays for human immunodeficiency virus type 1 (HIV-1) be applicable to diverse HIV-1 subtypes. ObjectivesTo evaluate NucliSens EasyQ™ HIV-1 assay for quantitation of common HIV-1 subtypes prevalent in South-east Asia. Study designOne hundred and nineteen plasma samples collected in Hong Kong and Cambodia were used to compare the performance of NucliSens EasyQ™ HIV-1 and COBAS Amplicor™ HIV-1 Monitor version 1.5 assays. Viral RNA extracted from the NucliSens MiniMAG™ was also used for HIV-1 subtyping. ConclusionsPerformance of NucliSens EasyQ™ was comparable to COBAS Amplicor™ for HIV-1 viral load monitoring. RNA extracts from NucliSens MiniMAG™ could be used for HIV-1 viral load monitoring, subtyping and drug resistance mutations detection. Our findings highlight the versatility of both NucliSens EasyQ™ and COBAS Amplicor™ in monitoring prevalent subtypes and rare circulating recombinant forms (CRFs) in the South-east Asia region. 1. Introduction  Plasma HIV-1 RNA level monitoring is highly recommended as an integral part in the implementation of anti-retroviral (ARV) therapy and predictor of disease prognosis (Mellors et al., 1997, O’Brien et al., 1997, Powderly et al., 1999). The introduction of highly active antiretroviral therapy (HAART) in clinical practice often results in rapid decline of plasma HIV-1 RNA. Highly sensitive viral load monitoring assays with a broad linear range are essential for the assessment of to ARV therapy (Raboud et al., 1998). Currently, various commercial assays including COBAS Amplicor™ HIV-1 Monitor version 1.5 (Roche Diagnostics, Branchburg, NJ), Versant HIV-1 RNA 3.0 assay, (Bayer Diagnostics, Tarrytown, NY) and NucliSens HIV-1 QT test (BioMérieux Inc., Boxtel, The Netherlands) are available for viral RNA quantitation in plasma samples, utilizing reverse-transcription polymerase chain reaction (RT-PCR), branched DNA signal amplification (bDNA) and nucleic acid sequence-based amplification (NASBA), respectively (Dyer et al., 1999, Ginocchio et al., 1999, Murphy et al., 2000). HIV-1 is characterized by a high genetic diversity and is classified into three distinct groups (M, N and O). Group M virus strain is further divided into subtypes and circulating recombinant forms (CRFs) (Los Alamos HIV database [http://hiv-web.lanl.gov/]). In recent years, subtypes B, C and CRF01_AE have played the major roles in the HIV-1 pandemic in the South-East Asia region (Oelrichs and Crowe, 2003). Emergence of CRF07_BC and CRF08_BC in China raised concern about the evolution of second generation inter-CRF recombinants (Yang et al., 2003), but data regarding the performance of commercially available HIV-1 monitoring assays for the detection of HIV-1 subtypes and CRFs prevalent in South-East Asia is very limited. In the present study, a new HIV-1 RNA quantitative assay, NucliSens EasyQ™ HIV-1 assay version 1.1 (BioMerieux Inc., Boxtel, The Netherlands) and the manual NucliSens MiniMAG™ (BioMerieux Inc., Boxtel, The Netherlands) extraction system were compared with COBAS Amplicor™ HIV-1 Monitor version 1.5 assay (Roche Diagnostics, Branchburg, NJ) on clinical plasma samples. NucliSens EasyQ™ assay is the first commercial HIV-1 viral load monitoring assay applying NASBA technology together with the real-time molecular beacons detection method (Van Beuningen et al., 2001). 2. Materials and methods 2.2. Quantitation of HIV-1 RNA Quantitation of HIV-1 RNA was performed following the manufacturers’ instructions. 2.2.1. COBAS Amplicor™ (RT-PCR) This assay applies RT-PCR technology targeting the gag p24 region of HIV-1 (Sun et al., 1998). Using 200 μL of plasma, the linear range is 400–750,000copies/mL (Sun et al., 1998). For plasma with viral loads above the upper detection limit, samples were diluted 100-fold with normal human plasma and re-tested. 2.2.2. NucliSens EasyQ™ (NASBA) This assay has a dynamic range from 50 to 3,000,000IU/mL (Yao et al., 2005). One millilter of plasma sample, together with the NucliSens EasyQ™ internal calibrator, was processed using the semi-automated NucliSens MiniMAG™ extractor. HIV-1 RNA and calibrator were subjected to co-amplification with the same primer but hybridized with different fluorescent-labeled probes. The calibrator and HIV-1 RNA differ by a short nucleotide sequence which is identified by sequence-specific molecular beacon probes (Weusten et al., 2002). Amplicons were monitored with a real-time NucliSens EasyQ™ analyzer. Similar to COBAS Amplicor™, NucliSens EasyQ™ assay uses the gag gene as the target site for detection. 2.3. Subtype diversity For subtype determination using HIV pol gene analysis, the same RNA extract from NucliSens MiniMAG™ extractor was amplified by RT-PCR followed by direct sequencing of the PCR amplicons (Yam et al., 2006). The Pregap4 and Gap4 modules of Staden Package (Medical Research Council-Laboratory of Molecular Biology, England) were used for sequence assembly and the HIV-1 subtype was determined using Stanford HIVdb database (http://hivdb6.stanford.edu). 2.4. Reproducibility, sensitivity and specificity The reproducibility and sensitivity of NucliSens EasyQ™ HIV-1 assay was assessed using the World Health Organization (WHO) HIV-1 standard (WHO 1st International Standard 1999, 97/656), which was a lyophilized HIV-1 subtype B virus at 100,000IU/mL after reconstitution. The standard was diluted in normal human plasma to concentrations of 100, 500, 1000 and 10,000IU/mL. For each concentration, five aliquots were extracted and assayed in triplicate. The mean, standard deviation and percentage of coefficient of variation (CV%) were estimated to determine the intra- and inter-run assay variations. Specificity of NucliSens EasyQ™ HIV-1 assay was evaluated with 25 HIV-1 serologically negative plasma samples from 10 healthy blood donors, 10 Hepatitis B virus (HBV)-infected and 5 Hepatitis C virus (HCV)-infected patients. All samples were confirmed to be HIV-1 RNA negative by COBAS Amplicor™ HIV-1 Monitor version 1.5. 2.5. Statistical analysis All statistical analyses were performed using log10-transformed values. According to the NucliSens EasyQ™ instruction booklet, the COBAS Amplicor™ value was converted from copies/mL to IU/mL by multiplying a factor of 0.51. The linear range of COBAS Amplicor™ was estimated between 204 and 382,500IU/mL. Correlation was used to assess the degree of linear association between two assays. Agreement between the two assays was analyzed by the Bland and Altman model (Bland and Altman, 1999). All statistical analyses were performed with the SPSS version 11.0 software (SPSS Inc., Chicago, IL). 3. Results 4. Discussion We found an overall good agreement between NucliSens EasyQ™ and COBAS Amplicor™ assay using randomly selected clinical specimens. The high correlation (r=0.777, p<0.001) and small mean difference between the two assays (0.0462log10IU/mL) are in agreement with recent studies: (1) NucliSens EasyQ™ versus COBAS Amplicor™: r=0.874; mean difference=0.0668 (Stevens et al., 2005), (2) NucliSens EasyQ™ versus NucliSens QT™: r=0.878; mean difference=0.28 (Yao et al., 2005), (3) NucliSens EasyQ™ versus Versant bDNA™: r=0.866 (de Mendoza et al., 2005). Six of 119 specimens (5.04%) showed invalid results in NucliSens EasyQ™ due to poor amplification during the NABAS reaction which had been reported previously (Stevens et al., 2005). As NucliSens EasyQ™ and COBAS Amplicor™ work on different principles, they are affected by inhibitors to different extend. This may account for the invalid result in NucliSens EasyQ™, but quantifiable result in COBAS Amplicor™. One specimen showed discordant result between the two assays (positive in NucliSens EasyQ™ but negative in CobasAmplicor™), which may be the result of the lower limit of detection of COBAS Amplicor™. In addition, nine specimens had viral loads greater than the detection limit of COBAS Amnplicor™, as demonstrated when their 100-fold diluted specimens were re-tested. These findings indicate the broader dynamic range of NucliSens EasyQ™ over COBAS Amplicor™ (NucliSens EasyQ™ 50–3,000,000IU/mL; COBAS Amplicor™ 204–382,500IU/mL), thus reducing running cost of NucliSens EasyQ ™ in routine application. This feature of NucliSens EasyQ™ is also important for management of ARV therapy (Yeni et al., 2004). Three specimens (two subtype B and one CRF01_AE) showed a mean difference outside the limit of agreement in the Bland–Altman plot analysis, indicated this is not subtype specific. Both assays are suitable for monitoring prevalent subtypes and rare circulating recombinant forms (CRFs) in the South-east Asia region. Our study is also concordant with previous findings that the dominant HIV-1 subtypes in Asia are B, C and CRF_01AE (Ruxrungtham et al., 2004). Similar correlation coefficient and mean difference was observed between the two assays for CRF01_AE and subtype B. A recent study in South Africa revealed that the performance of NucliSens EasyQ™ assay is comparable to COBAS Amplicor™ for subtype C isolates (Stevens et al., 2005). In the current study, the detection of CRF07_BC, which is commonly circulating among the intravenous drug users in China, emphasizes the versatility of NucliSens EasyQ™ on different CRFs of HIV-1 (Su et al., 2000), and indicates that both assays are suitable for viral load determination of diverse HIV-1 subtypes. RNA extracts from NucliSens MiniMAG™ extractor can also be used for subtype determination. RNA extracts of a few samples were also applied successfully to monitor drug resistance mutations in pol gene sequence as described previously (data not shown) (Yam et al., 2006). The sensitivity of NucliSens EasyQ™ assay in this study, reported as the detection limit and the 95% positive rate, is comparable to the reported value of COBAS Amplicor™ (Sun et al., 1998). As HIV-1 patients are frequently co-infected with HBV or HCV, the high specificity of NucliSens EasyQ™ is essential for monitoring the HIV-1 viral load in the presence of other blood-borne viruses. We were able to process 48 specimens using the NucliSens EasyQ™ system within an 8-h working day. The semi-automatic NucliSens MiniMAG™ extractor significantly reduced the hands on time for nucleic acid isolation and the NucliSens EasyQ™ analyzer can accommodate 48 specimens per run. By manual extraction of nucleic acid, a single run of COBAS Amplicor™ can only complete 18 specimens in a working day. NucliSens EasyQ™ provides a desirable alternative to existing commercial assays for HIV-1 viral load monitoring. Acknowledgement The study was supported by the AIDS Trust Fund of Hong Kong Special Administrative Region Government (grant no. MSS-099R). References Bland and Altman, 1999. 1.Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Meth Med Res. 1999;8(2):135–160. de Mendoza et al., 2005. 2.de Mendoza C, Koppelman M, Montes B, Ferre V, Soriano V, Cuypers H, et al. Multicenter evaluation of the NucliSens EasyQ HIV-1 version 1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Meth. 2005;127(1):54–59. Dyer et al., 1999. 3.Dyer JR, Pilcher CD, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1999;37(2):447–449. MEDLINE Ginocchio et al., 1999. 4.Ginocchio CC, Tetali S, Washburn D, Zhang F, Kaplan MH. Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays. J Clin Microbiol. 1999;37(4):1210–1212. MEDLINE Mellors et al., 1997. 5.Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954. MEDLINE Murphy et al., 2000. 6.Murphy DG, Cote L, Fauvel M, Rene P, Vincelette J. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2000;38(11):4034–4041. MEDLINE O’Brien et al., 1997. 7.O’Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997;126(12):939–945. MEDLINE Oelrichs and Crowe, 2003. 8.Oelrichs RB, Crowe SM. The molecular epidemiology of HIV-1 in South and East Asia. Curr HIV Res. 2003;1(2):239–248.
CrossRef
Powderly et al., 1999. 9.Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13(14):1873–1880. MEDLINE |
CrossRef
Raboud et al., 1998. 10.Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20copies/mL is required to achieve a long-term response to therapy. AIDS. 1998;12(13):1619–1624. MEDLINE |
CrossRef
Ruxrungtham et al., 2004. 11.Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004;364(9428):69–82.
CrossRef
Stevens et al., 2005. 12.Stevens W, Wiggill T, Horsfield P, Coetzee L, Scott LE. Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Meth. 2005;124(1/2):105–110. Su et al., 2000. 13.Su L, Graf M, Zhang Y, von Briesen H, Xing H, Kostler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol. 2000;74(23):11367–11376.
CrossRef
Sun et al., 1998. 14.Sun R, Ku J, Jayakar H, Kuo JC, Brambilla D, Herman S, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36(10):2964–2969. MEDLINE Van Beuningen et al., 2001. 15.Van Beuningen R, Marras SA, Kramer FR, Oosterlaken T, Weusten J, Borst G, et al. Development of a high throughput detection system for HIV-1 using real-time NASBA based on molecular beacons. In: Raghavachari R, Tan WH editor. Genomics and proteomics technologies, Proceedings of SPIE, vol. 4264. Washington, DC: Society of Photo-optical Instrumentation Engineers; 2001;p. 66–71. Weusten et al., 2002. 16.Weusten JJ, Carpay WM, Oosterlaken TA, van Zuijlen MC, van de Wiel PA. Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucl Acids Res. 2002;30(6):e26. Yam et al., 2006. 17.Yam WC, Chen JH, Wong KH, Chan K, Cheng VC, Lam HY, et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol. 2006;35:454–457. Abstract | Full Text |
Full-Text PDF (93 KB)
|
CrossRef
Yang et al., 2003. 18.Yang R, Kusagawa S, Zhang C, Xia X, Ben K, Takebe Y. Identification and characterization of a new class of human immunodeficiency virus type 1 recombinants comprised of two circulating recombinant forms, CRF07_BC and CRF08_BC, in China. J Virol. 2003;77(1):685–695.
CrossRef
Yao et al., 2005. 19.Yao J, Liu Z, Ko LS, Pan G, Jiang Y. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Meth. 2005;129(1):40–46. Yeni et al., 2004. 20.Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2):251–265.
CrossRef
a Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China b Integrated Treatment Centre, Special Preventive Programme, Centre of Health Protection, Department of Health, Hong Kong SAR, China c Department of Medicine, The Queen Elizabeth Hospital, Hong Kong SAR, China d Department of Pathology, The Queen Elizabeth Hospital, Hong Kong SAR, China  Corresponding author. Tel.: +852 28554892; fax: +852 28551241.
PII: S1386-6532(06)00372-6 doi:10.1016/j.jcv.2006.10.002 © 2006 Elsevier B.V. All rights reserved. | |
|
FULL TEXT00372-6/journalimage?img=PIIS1386653206003726.gr1.lrg.gif&fig=fig1&kwhquery=&issn=1386-6532&ishighres=false&allhighres=false&free=yes','journalimage');)
00372-6/journalimage?img=PIIS1386653206003726.gr2.lrg.gif&fig=fig2&kwhquery=&issn=1386-6532&ishighres=false&allhighres=false&free=yes','journalimage');)
